Background: Fluoropyrimidines (e.g., 5-fluorouracil, capecitabine) are antineoplastic agents commonly used in the setting of gastrointestinal cancer. Dihydropyridine dehydrogenase (DPD), encoded by the DPYD gene, is the enzyme responsible for up to 85% of 5-FU catabolism into inactive metabolites. Decreased or no function genetic variations in DPYD are rare but increase risk of potentially fatal adverse effects (e.g., myelosuppression) due to decreased metabolism of 5-FU. The extent of which DPD enzyme activity is impaired varies among individual decreased function DPYD variants.
Case presentation: A 75-year-old female was diagnosed with stage III squamous cell carcinoma of the anal canal. She was scheduled to receive therapy consisting of mitomycin C (8 mg/m2) administered over 30 min and continuous infusion 5-FU (4000 mg/m2) over 96 h for 2 cycles with concurrent radiotherapy. Prior to treatment, the patient underwent DPYD genotyping which revealed she was a heterozygous carrier of the decreased function allele, c.2846 A > T. In accordance with Clinical Pharmacogenomics Implementation Consortium (CPIC) guideline recommendations, the dose of 5-FU for cycle 1 was reduced by 50%. Despite the dose reduction, she still experienced mucositis (G3), neutropenia (G3), diarrhea (G2), nausea and vomiting (G2), and dyspnea (G2).
Conclusion: This case report supports the clinical utility of pre-emptive DPYD genotyping to guide initial 5-FU dosing in intermediate metabolizers, and it suggests that all patients still require close monitoring and some (particularly carriers of c.2846 A > T) may require an initial dose reduction greater than the recommended 50% to prevent severe toxicity.
Keywords: DPD; DPYD; Fluoropyrimidine; Pharmacogenetics; Toxicity.
© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.